

15 November 2005

The Manager  
Company Announcements  
Australian Stock Exchange  
4<sup>th</sup> Floor  
20 Bridge Street  
SYDNEY NSW 2000

Dear Sir

### **Resonance Health closes SPP and appoints US Corporate Advisors**

Resonance Health (ASX: RHT) today announced that the Share Purchase Plan (SPP) is closed after raising of \$795,000 from eligible shareholders. The Company has also appointed US investment bank, Montgomery Pacific Group (MPG), as its US corporate advisors.

MPG is a boutique investment bank founded by leaders from the banking and life science industries with strong connections into healthcare communities in the US. Located in Irvine, California, and Bethesda, Maryland, MPG will assist Resonance Health in US-based strategic business development opportunities. Activities to be conducted by MPG are directed towards securing long term value creation, including securing accelerated market penetration for Resonance Health's lead technology, FerriScan<sup>®</sup>, and further development of our product pipeline, including the new Fibrosis test.


The terms of engagement for MPG include a small cash component and up to 833,333 shares, paid in tranches on achievement of agreed milestones, with additional fees and options payable on commercial terms upon completion of certain specified activities. An issue of 416,667 shares have been provided to MPG as the initial instalment of the retainer.

Dr James Williams, Managing Director of Resonance Health said: "Strong US market penetration is an important stage in the commercial roll-out of our technology. We have already signed a memorandum of understanding with a major US radiology chain which complements the clinical programs we are running with Novartis and the Thalassemia Clinical Research Network. MPG will aid in the strategic acceleration of this process, primarily focusing on commercial alliance opportunities."

The combination of the recent placement and closing of the SPP results in the company having cash reserves of \$2.4 million.

#### **About Montgomery Pacific Group:**

Montgomery Pacific is a merger and acquisition specialist with a focus in the life sciences. The partnership has a track record of finding, negotiating and financing revenue positive transactions the sector.



**Roger Greene**

Mr. Greene worked with the various funds the Robert M. Bass Group (Brazos Fund and Lone Star Fund) in Texas as a principal and as general counsel. For Lone Star, Mr. Greene was responsible for negotiation and structuring of asset acquisitions from foreign entities. Prior to that time, he also worked on resolution and management of the assets of American Savings and Loan Association.

Education: AB Economics, Harvard College, magna cum laude, phi beta kappa; JD Harvard Law School, cum laude.

**Dr. John Holaday**

Along with his partnership in Montgomery Pacific Group, Dr. Holaday is the co-founder and Chairman of HarVest Bank of Maryland, a commercial retail bank. He is the founder of EntreMed (ENMD, NASDAQ), Inc. and until his retirement in 2003, has served as its President and CEO and a Director since 1992 and its Chairman since 1995. Prior to ENMD, he was the co-founder of Medicis (MRX, NYSE) Pharmaceutical Corp. where he served as the Senior Vice President for Research and development and Member of the Board of Directors.


Dr. Holaday's academic appointments include Visiting Associate Professor of Anesthesiology and Critical Care Medicine at the Johns Hopkins University School of Medicine

Education: BS, University of Alabama MS, University of Alabama, PhD, University of California, San Francisco, with Honors

**Michael Dalsin**

Mr. Dalsin has worked in international investment banking and deal-making with investments by Morgan Stanley Managing Director's funds in London, Hong Kong and New York. He participated as a lead banker and negotiator for a number of small and medium market international acquisitions for both American and English companies. Mr. Dalsin both lived and worked in Europe (London, England), South Asia (Hong Kong and Singapore), and South America (Caracas, Venezuela).

Education: BS, Economics; University of Wisconsin – Madison.



**About Resonance Health Ltd:**

Resonance Health (ASX: RHT) is an Australian Healthcare company specialising in the development and commercialisation of magnetic resonance imaging (MRI) related technology for the quantitative measurement of iron levels in the human body.

Our mission is to develop and market our technologies to assist in the diagnosis and management of patients suffering from iron-related conditions, whilst delivering significant added value for our MRI customers who deliver our service through their networks.

In 2005, RHT began the global commercial launch of FerriScan®, its world leading non-invasive tool for measuring liver iron levels.

The FerriScan service involves an MRI scan followed by off-site processing of the images by RHT using its patented methodology to generate the liver iron concentration result. MR data is transmitted electronically via a secure data process to the RHT analysis centre from anywhere in the world. The test requires no new equipment purchase at the MRI centre level.

FerriScan provides a significant improvement over current blood markers and invasive surgical procedures. This improvement leads to increased clinical efficiency and accuracy in diagnosis, in addition to allowing optimisation of treatment programs for iron-related disorders. FerriScan is now positioned to become a routine part of the clinical diagnosis and management of iron loading disorders as well as playing a major role in the testing and monitoring of drugs used to treat these conditions.

FerriScan has received regulatory clearance to be marketed in the USA, Australia, UK and Europe. Further information about Resonance Health and FerriScan® can be obtained from the following websites: [www.resonancehealth.com](http://www.resonancehealth.com) and [www.ferriscan.com](http://www.ferriscan.com).

<b>Media and Investor Relations</b>	<b>Resonance Health</b>
Rebecca Piercy Buchan Consulting T - +61 3 9866 4722 M – 0422 916 422 Email: <a href="mailto:rpiercy@bcg.com.au">rpiercy@bcg.com.au</a>	Dr James Williams Managing Director Resonance Health Limited T - +61 8 9286 5300 M - 0409 050 519 Email: <a href="mailto:jamesw@ferriscan.com">jamesw@ferriscan.com</a>